Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | AOC3 | Q16853 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | PTGDR2 | Q9Y5Y4 | 9/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.33 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.31 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.31 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.31 |
| ▸ | TSHR | P16473 | 2/20 | 0.31 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1970708 | 0.84 | AOC3 (0.65) | AOC3HTTPTGDR2CYP3A4CHRM2 | |
| SCHEMBL12312248 | 0.82 | AOC3 (0.57) | AOC3PTGDR2CYP2D6 | |
| SCHEMBL12312230 | 0.81 | AOC3 (0.58) | AOC3PTGDR2 | |
| SCHEMBL12312253 | 0.80 | AOC3 (0.53) | AOC3PTGDR2CYP3A4CYP2D6 | |
| SCHEMBL12312240 | 0.80 | AOC3 (0.51) | AOC3PTGDR2 | |
| SCHEMBL12312236 | 0.79 | AOC3 (0.52) | AOC3PTGDR2 | |
| SCHEMBL12312244 | 0.79 | AOC3 (0.74) | AOC3PTGDR2CYP3A4CHRM2CHRM1 | |
| SCHEMBL12312222 | 0.79 | AOC3 (0.47) | AOC3HTTPTGDR2TSHR | |
| SCHEMBL12312296 | 0.78 | AOC3 (0.44) | AOC3PTGDR2 | |
| SCHEMBL12312290 | 0.78 | AOC3 (0.51) | AOC3PTGDR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11040969-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2021-06-22 | — | — | US | disclosed |
| EP-3777846-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | BenevolentAI Cambridge Limited (GB) | 2021-02-17 | — | — | EP | disclosed |
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN, LLC | 2020-12-24 | — | — | US | disclosed |
| US-10399973-B2 | Compounds I | Benevolentai Cambridge Limited (GB) | 2019-09-03 | — | — | US | disclosed |
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-20180118744-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2018-05-03 | — | — | US | disclosed |
| US-9890160-B2 | Compounds I | PROXIMAGEN LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| US-9890160-B2 | Compounds I | PROXIMAGEN LIMITED (GB) | 2018-02-13 | — | — | US | disclosed |
| WO-2017098236-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | PROXIMAGEN LIMITED (GB) | 2017-06-15 | — | — | WO | disclosed |
| US-20170044157-A1 | NEW COMPOUNDS I | PROXIMAGEN, LLC | 2017-02-16 | — | — | US | disclosed |
| US-9035066-B2 | Method of using 4,5,6,7-tetrahydroimidazo[4,5-C]pyridine compounds | PROXIMAGEN LIMITED (GB) | 2015-05-19 | — | — | US | disclosed |
| WO-2014199171-A1 | NEW THERAPEUTIC USES OF ENZYME INHIBITORS | PROXIMAGEN LIMITED (GB) | 2014-12-18 | — | — | WO | disclosed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | disclosed |
| US-8569338-B2 | Methods of using 4, 5, 6, 7-tetrahydroimidazo-[4,5-c]pyridine compounds | PROXIMAGEN LTD. (GB) | 2013-10-29 | — | — | US | disclosed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-20120302583-A1 | New Compounds I | PROXIMAGEN LIMITED (GB) | 2012-11-29 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-8263616-B2 | 4,5,6,7-tetrahydroimidazo[4,5-c]pyridine compounds | PROXIMAGEN LTD (GB) | 2012-09-11 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
| US-20110207746-A1 | NEW COMPOUNDS I | PROXIMAGEN LIMITED (GB) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200397764-A1 | VAP-1 INHIBITORS FOR TREATING PAIN | VAPB, VAPA, OPRL1 | AOC3 55/4885HTT 2186/4885PTGDR2 2738/4885 |
| US-10399973-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885HTT 1135/4885PTGDR2 1209/4885 |
| US-20110207746-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885HTT 1533/4885PTGDR2 823/4885 |
| US-20120302583-A1 | New Compounds I | SSB, NFKBIA, NOD1 | AOC3 111/4885HTT 1423/4885PTGDR2 819/4885 |
| US-11040969-B2 | Compounds I | SSB, SQLE, ALOX15B | AOC3 63/4885HTT 1135/4885PTGDR2 1209/4885 |
| US-20170044157-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885HTT 1533/4885PTGDR2 823/4885 |
| US-20180118744-A1 | NEW COMPOUNDS I | SSB, NFKBIA, ALOX15B | AOC3 54/4885HTT 1533/4885PTGDR2 823/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.